Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
Evaxion Biotech A / S, a clinical-stage artificial intelligence and immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company is headquartered in Hoersholm, Denmark.
52W High
$17.75
52W Low
$1.20
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.14
Valuation
Attractive
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
3.57
EV/EBITDA (<8 favorable)
-0.59
EV/Revenue (<3 favorable)
4.72
P/S (TTM) (<3 favorable)
5.81
P/B (<3 favorable)
2.96
Ownership
Retail‑heavySource: Overview
Insiders (1–5% typical)
23.07%
Institutions (25–75% balanced)
6.82%
Shares Outstanding
6,316,600
Float
177,287,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
3,176,000
Gross Profit (TTM)
3,176,000
EPS (TTM)
-6.50
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-117.30%
ROE (TTM) (>15% strong)
-3.20%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.76
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—